Streetbeat News

ALMS

Alumis Inc.

Industry

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Open

9.50

Mkt cap

418M

Volume

181K

High

10.64

P/E Ratio

-2.54

52-wk high

13.53

Low

8.22

Div yield

N/A

52-wk low

8.22

Samsara Biocapital LP has reported a 6.9% stake in Alumis as of July 1, according to an SEC filing.

Portfolio Pulse from Benzinga Newsdesk

August 27, 2024 | 8:30 pm

Cantor Fitzgerald analyst Eric Schmidt has reiterated an Overweight rating on Alumis (NASDAQ:ALMS).

Portfolio Pulse from Benzinga Newsdesk

August 19, 2024 | 3:08 pm

Alumis reported a Q2 net loss of $56.5 million, which is a significant increase from the $36.3 million loss reported in the same quarter last year.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 8:59 pm

Alumis shares are trading higher after the company announced the initiation of the Onward Phase 3 clinical program for ESK-001.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 6:58 pm

Alumis has initiated the ONWARD Phase 3 clinical program for ESK-001, targeting moderate-to-severe plaque psoriasis. The study aims to achieve co-primary endpoints PASI 75 and sPGA 0/1 at 24 weeks to support a U.S. regulatory submission. Topline data is expected in 2026.

Portfolio Pulse from Benzinga Newsdesk

July 29, 2024 | 12:03 pm

Alumis Inc. (NASDAQ: ALMS), a clinical-stage biopharmaceutical company, has attracted attention from analysts at Guggenheim Partners and Cantor Fitzgerald. Both firms initiated coverage with positive ratings, citing the potential of Alumis' lead asset ESK-001 and its brain-penetrant TYK2 inhibitor A-005. Guggenheim set a price target of $32, while Cantor highlighted the company's modest valuation and commercial potential. Alumis recently raised $250 million through its IPO and private placement.

Portfolio Pulse from Vandana Singh

July 24, 2024 | 7:18 pm

Cantor Fitzgerald analyst Eric Schmidt has initiated coverage on Alumis (NASDAQ:ALMS) with an Overweight rating.

Portfolio Pulse from vivek@benzinga.com

July 24, 2024 | 9:39 am

Guggenheim has initiated coverage on Alumis (NASDAQ:ALMS) with a Buy rating and set a price target of $32.

Portfolio Pulse from Benzinga Newsdesk

July 23, 2024 | 3:15 pm

Cantor Fitzgerald has initiated coverage on Alumis (NASDAQ:ALMS) with an Overweight rating and set a price target of $13.

Portfolio Pulse from Benzinga Newsdesk

July 23, 2024 | 12:21 pm

Leerink Partners has initiated coverage on Alumis (NASDAQ:ALMS) with an Outperform rating and a price target of $29.

Portfolio Pulse from Benzinga Newsdesk

July 23, 2024 | 10:25 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.